SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Aequus Pharmaceuticals (AQSZF)

AQSZF RSS Feed
Add AQSZF Price Alert      Hide Sticky   Hide Intro
Moderator: BioSpecialist
Search This Board:
Last Post: 9/26/2016 9:16:23 PM - Followers: 1 - Board type: Free - Posts Today: 0
AQSZF (MC $10 M) 2 Marketed Drugs + 3 close to Approval including a Potential Blockbuster = SUPER LIFETIME OPPORTUNITY !!!!

This undiscovered low float rocket is definitely the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Get some of this Goldmine before she gets discovered .Management alone holding over 16 Million shares Ceo bought 840k shares at 0.30 just a few days ago .GLTA


Aequus Pharma (AQS.V) (AQSZF)

Market-Cap: $10 M
Price: 0.21

Shares out: 54 Million

Presentation August 2016

http://www.aequuspharma.ca/Investors/Aequus%20Pharmaceuticals%20August%202016.pdf



Marketed Products:

Tacrolimus IR

Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)



Vistitan
Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.

Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017

Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017



NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License (If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)


AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse.




 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AQSZF
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#12   Indeed, company with tiny float and low volume Maple tree 09/26/16 09:16:23 PM
#11   load up guys while its still dirt cheap BioSpecialist 09/26/16 02:16:52 PM
#10   Great Management here / Massive undervalued ( Market BioSpecialist 09/26/16 10:16:04 AM
#9   Game starts and grabe as much as possible Maple tree 09/26/16 10:09:51 AM
#8   AQZSF is definitely under many people's radar and Maple tree 09/24/16 10:48:09 PM
#7   once investors discover this goldmine then it will BioSpecialist 09/23/16 03:27:07 PM
#6   Still a tiny company. With more revenue realized Maple tree 09/23/16 10:48:03 AM
#5   Total Market cap is c$16.2 Million (= US$12.4 Million) BioSpecialist 09/22/16 12:56:11 PM
#4   Thanks for information. Do you know what is Maple tree 09/22/16 12:39:35 PM
#3   exactly the main listing is in canada and BioSpecialist 09/22/16 11:40:07 AM
#2   Very solid company and is this company also Maple tree 09/22/16 11:32:13 AM
#1   Interview with Ceo Doug Janzen BioSpecialist 09/22/16 07:33:00 AM
PostSubject